WO2024063543A1 - Composition pour la prévention ou le traitement du cancer à l'aide d'une polythérapie, comprenant une souche de lactobacillus plantarum et un médicament à base de plantes - Google Patents

Composition pour la prévention ou le traitement du cancer à l'aide d'une polythérapie, comprenant une souche de lactobacillus plantarum et un médicament à base de plantes Download PDF

Info

Publication number
WO2024063543A1
WO2024063543A1 PCT/KR2023/014310 KR2023014310W WO2024063543A1 WO 2024063543 A1 WO2024063543 A1 WO 2024063543A1 KR 2023014310 W KR2023014310 W KR 2023014310W WO 2024063543 A1 WO2024063543 A1 WO 2024063543A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
strain
preventing
herbal medicine
active material
Prior art date
Application number
PCT/KR2023/014310
Other languages
English (en)
Korean (ko)
Inventor
장명호
양보기
김아람
Original Assignee
주식회사 지아이바이옴
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 지아이바이옴 filed Critical 주식회사 지아이바이옴
Priority claimed from KR1020230125600A external-priority patent/KR20240040655A/ko
Publication of WO2024063543A1 publication Critical patent/WO2024063543A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/066—Clavicipitaceae
    • A61K36/068—Cordyceps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • composition for treating cancer using combination therapy containing Lactobacillus plantarum strains and herbal medicine.
  • Microbiome refers to microorganisms and their entire genetic information existing in a specific environment. In addition to the human body, microbiome information is being used in various fields such as animals, agriculture, the ocean, and the environment. In particular, with the development of human microbiome research based on the development of genetic information analysis and data analysis technology, based on this, microbiome information is being used. The growth of the diagnostic and healthcare industries is expected.
  • cancer is considered one of the major health problems.
  • colon cancer is the fourth most common malignant tumor in the world and the third leading cause of cancer death.
  • surgery is the most effective treatment method.
  • the survival rate from early stage 1 to stage 3 reaches 70-90%, but in the final stage 4, the survival rate drops sharply to 15%.
  • herbal medicine has been traditionally used to treat human diseases and protect the body for a long time.
  • most of them are of plant origin and are mainly based on complex prescriptions of herbal medicinal ingredients. Therefore, interest is growing due to the chemical side effects of many synthetic drugs, which have complex effects and few side effects.
  • Combination therapy is the use of two or more drugs or methods simultaneously or in relatively quick succession.
  • the side effects of two or more treatment modalities used in combination therapy may be additive or less than additive, while the therapeutic effects may be additive or greater than additive.
  • the effects that occur when each component is administered together can be expected to have a greater synergistic effect than the sum of the effects that occur when each component is administered alone. Therefore, there is a need for the development of combination therapy that can synergistically increase the effect of treatment using a single ingredient.
  • One aspect includes as an active ingredient a first active material comprising a Lactobacillus plantarum strain, a culture of the strain, a lysate of the strain, or a mixture thereof, and a second active material containing a herbal medicine. do or;
  • the present invention provides a pharmaceutical composition for preventing or treating cancer, which includes the first active substance as an active ingredient and the second active substance is administered in combination.
  • Another aspect includes as an active ingredient a first active material comprising a Lactobacillus plantarum strain, a culture of the strain, a lysate of the strain, or a mixture thereof, and a second active material containing a herbal medicine. do or;
  • the present invention provides a health functional food for preventing or improving cancer, which includes the first active substance as an active ingredient and the second active substance is administered in combination.
  • a first active material containing a Lactobacillus plantarum strain, a culture of the strain, a lysate of the strain, or a mixture thereof, and a second active material containing a herbal medicine are used as active ingredients.
  • a kit for preventing or treating cancer which includes the first active substance as an active ingredient and the second active substance is administered in combination.
  • a first active material containing a Lactobacillus plantarum strain, a culture of the strain, a lysate of the strain, or a mixture thereof, and a second active material containing a herbal medicine are used as active ingredients.
  • a first active material containing a Lactobacillus plantarum strain, a culture of the strain, a lysate of the strain, or a mixture thereof, and a second active material containing a herbal medicine are used as active ingredients.
  • Another aspect is a first active material comprising an effective amount of a Lactobacillus plantarum strain, a culture of the strain, a lysate of the strain, or a mixture thereof, and a second active material comprising an effective amount of a herbal medicine.
  • a first active material comprising an effective amount of a Lactobacillus plantarum strain, a culture of the strain, a lysate of the strain, or a mixture thereof
  • a second active material comprising an effective amount of a herbal medicine.
  • Another aspect includes Lactobacillus plantarum strains, cultures of the strains, lysates of the strains, or mixtures thereof for the production of pharmaceutical agents or health functional foods for preventing or treating cancer.
  • a composition comprising as active ingredients a first active material and a second active material including an herbal medicine; Alternatively, it provides the use of a composition comprising the first active material as an active ingredient and the second active material being administered in combination.
  • Lactobacillus genus strain specifically Lactobacillus plantarum GB104 strain, which has anticancer activity, for example, anticancer activity against colon cancer.
  • Lactobacillus is a genus of aerobic or facultative anaerobic Gram-positive bacilli widely distributed in nature. Microorganisms belonging to the Lactobacillus genus include Lactobacillus plantarum and Sakei. As a result of research to develop a new strain with excellent anticancer effect, the present inventors selected Lactobacillus plantarum GB104 as an anticancer candidate strain. The strain was deposited at the Korea Research Institute of Bioscience and Biotechnology Biological Resources Center under the deposit number KCTC14107BP on January 14, 2020. The strain corresponds to a probiotic strain, is harmless to the human body, and can be used without side effects.
  • Lactobacillus ( Lactobacillus ) has been renamed to Limosilactobacillus or Lactiplantibacillus , and the changed strain names in this specification can be used interchangeably.
  • Lactobacillus plantarum was changed to Lactiplantibacillus plantarum .
  • Lactobacillus plantarum GB104 may be used together with L. Plantarum GB104 strain or Lactobacillus plantarum GB104 strain (Accession Number: KCTC14107BP).
  • the strain may be a strain deposited under accession number KCTC14107BP.
  • the strain may be a strain containing a 16S rRNA gene consisting of the nucleotide sequence of SEQ ID NO: 1.
  • the strain may be a strain having 16S rRNA comprising the nucleotide sequence of SEQ ID NO: 1 or a 16s rRNA comprising a nucleotide sequence having 97% or more nucleotide sequence identity thereto. Specifically, it has at least 93%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, 99.9% or 100% homology with the nucleotide sequence consisting of SEQ ID NO: 1 of the present specification.
  • the strain may be live cells, dead cells, or a cytoplasmic fraction obtained by disrupting the strain, and preferably may be live cells.
  • the term “culture” may be used interchangeably with “culture supernatant,” “culture supernatant,” “conditioned culture,” or “conditioned medium,” and can be used interchangeably with “culture supernatant,” “conditioned culture medium,” or “conditioned medium” to allow strains of the genus Lactobacillus to grow and survive in vitro. It may refer to the entire medium containing the strain, its metabolites, extra nutrients, etc. obtained by culturing the strain in a medium capable of supplying nutrients for a certain period of time.
  • the culture refers to a product obtained by culturing a probiotic strain in a known medium, and the product may or may not include the strain itself.
  • the medium may be selected from known liquid media or solid media, for example, MRS liquid medium, GAM liquid medium, MRS agar medium, GAM agar medium, and BL agar medium, but is not limited thereto.
  • lysate may be used interchangeably with “lysate”, meaning a solution or suspension of cells of a microorganism such as Lactobacillus plantarum in an aqueous medium o broken down.
  • Cell lysates include, for example, macromolecules such as DNA, RNA, proteins, peptides, carbohydrates, lipids, etc. and/or micromolecules such as amino acids, sugars, fatty acids, etc., or fractions thereof.
  • the lysate also contains cell debris, which may be smooth or granular in structure.
  • the culture medium may include the culture medium itself, its concentrate, or freeze-dried product obtained by cultivating the strain, or the culture supernatant obtained by removing the strain from the culture medium, its concentrate, or freeze-dried product.
  • the culture medium may be obtained by culturing Lactobacillus plantarum in an appropriate medium (e.g., MRS plate medium) at any temperature above 10°C or below 40°C for a certain period of time, for example, 4 to 50 hours. .
  • an appropriate medium e.g., MRS plate medium
  • the first active material comprising at least one member selected from the group consisting of the strain, a culture of the strain, a lysate of the strain, or an extract of the bacterium, culture, and lysate has anticancer activity. You can.
  • the anticancer activity may be an activity that delays the development of a tumor or inhibits the growth rate of a tumor.
  • the first active substance may have tumor growth inhibitory activity.
  • the first active substance may induce apoptosis of cancer cells.
  • the anticancer activity is a growth inhibitory activity of cancer cells, which reduces the cancer cell survival rate by 90% to 98% when the supernatant of Lactobacillus Plantarum GB104 strain is treated with colon cancer cells HCT116, or Lactobacillus Plantarum GB104
  • the activity reduces tumor volume by 10% to 90% or tumor weight by 10% to 50% compared to the control group not administered the strain. It may be.
  • the anti-cancer activity is an activity that induces apoptosis of cancer cells, and when the supernatant of Lactobacillus Plantarum GB104 strain was treated with colon cancer cells HCT116, the initial apoptosis induction of cancer cells was induced without administering the strain.
  • the activity may be 5 to 9 times increased compared to the control group.
  • the first active substance may have anticancer activity, specifically, anticancer activity against colon cancer.
  • cancer refers to a physiological condition in animals, typically characterized by abnormal or uncontrolled cell growth. Cancer and cancer pathology include, for example, metastasis, interference with normally functioning surrounding cells, release of cytokines or other secreted products at abnormal levels, inhibition or enhancement of inflammatory or immunological responses, neoplasia, and premalignancy. ), malignancy, or involvement of surrounding or distant tissues or organs, such as lymph node invasion.
  • the cancer may be gastrointestinal cancer or non-gastrointestinal cancer.
  • the gastrointestinal cancer is a malignant tumor that occurs in the gastrointestinal tract, such as the esophagus, stomach, small intestine, or large intestine.
  • the gastrointestinal cancer includes, for example, esophageal cancer, gallbladder cancer, liver cancer, biliary tract cancer, pancreatic cancer, stomach cancer, small intestine cancer, colon cancer, colon cancer, and anal cancer. It may be one or more cancers selected from the group consisting of rectal cancer, but is not limited thereto, and in one example, it may be colon cancer.
  • the non-gastrointestinal cancer includes, without limitation, malignant tumors occurring in organs other than the gastrointestinal tract or digestive system, for example, hematological cancer, leukemia, acute myeloid leukemia, neuroblastoma, retinoblastoma, lung cancer, head and neck cancer, salivary gland cancer, melanoma, It may be, but is not limited to, laryngeal cancer, prostate cancer, breast cancer, bladder cancer, kidney cancer, multiple myeloma, cervical cancer, thyroid cancer, ovarian cancer, urethral cancer, skin cancer, osteosarcoma, glioblastoma, brain tumor, or lymphoma.
  • malignant tumors occurring in organs other than the gastrointestinal tract or digestive system for example, hematological cancer, leukemia, acute myeloid leukemia, neuroblastoma, retinoblastoma, lung cancer, head and neck cancer, salivary gland cancer, melanoma
  • It may be, but is not limited to, laryngeal cancer
  • the cancer may be colon cancer, and the colon cancer includes occurring in one or more regions selected from the group consisting of ascending colon, transverse colon, descending colon, sigmoid colon, and rectal mucosa.
  • the colon cancer may be one or more types selected from the group consisting of adenocarcinoma, lymphoma, malignant carcinoid, leiomyosarcoma, Kaposi's sarcoma, and squamous cell carcinoma, but is not limited thereto.
  • the first active substance may contain Lactobacillus plantarum strain alone as an active ingredient, or may include one or more pharmaceutically acceptable carriers, excipients, or diluents.
  • the second active material may include an herbal medicine.
  • the herbal medicine may be one or more selected from the group consisting of Cordyceps sinensis, yam, bellflower root, Sanghwang mushroom, Hyeoncho, and combinations thereof.
  • the term "herbal medicine” is defined in the Pharmaceutical Affairs Act as a raw medicinal material used to manufacture herbal medicine or herbal medicine preparations. Herbal medicines may have different medicinal properties depending on the processing laws and regulations, so processing and manufacturing methods are important.
  • the herbal medicine may be Cordyceps sinensis, yam, bellflower root, Sanghwang mushroom, or Hyeoncho, but is not limited thereto. At this time, the herbal medicine may be used in powder or extract form.
  • Cordyceps militaris in a broad sense refers to all types of mushrooms parasitic on insects, typically including Cordyceps militaris , whose host is a butterfly, C. sobolifera , whose host is a cicada, and bees.
  • the host is Cordyceps sinensis ( C. sphecocephala ). It contains cordycepin, and has been reported to have anti-cancer, immune strengthening, skin beautification, fatigue recovery, and anti-aging effects.
  • yam Dioscorea japonica
  • yam Dioscorea japonica
  • the rhizome of the yam contains amylase, betasin, mucin, mucilage, and allantoin ( It contains allantoin, saponin, tannin, and polyphenol, and has been reported to have antioxidant, anti-inflammatory, and anticancer effects.
  • bellflower root ( Platycodon grandiflorum ) refers to a perennial herb or its root belonging to the Campanula family.
  • Polysaccharides such as inulin, triterpenoids, triterpene, saponins such as platicodin, platycodigenin, polygalacin, etc. Containing a large amount of this, it has been reported to have effects such as immune enhancement, anti-inflammation, anti-ulcer, skin soothing effect, antipyretic, blood circulation, detoxification, and antibacterial effect.
  • Phellinus linteus is a perennial wood-rot fungus that grows naturally on mulberry trees, etc., and is also called woody mud mushroom. It has been reported to have anticancer, immune, and antioxidant effects. Specifically, it has been reported that the pharmacological action of Sanghwa mushrooms enhances immune function when combined with chemotherapy after resection surgery for liver cancer, including gastric cancer, esophageal cancer, duodenal cancer, colon cancer, and rectal cancer, which are cancers of the digestive system.
  • Hyeoncho refers to a perennial herb belonging to the Geranium nepalense subsp. Thunbergii family, Geraniaceae, and is also called Gwangjipul, Hyeoncho, and Hyeonchicho.
  • the main components of Hyacinth herb extract include quercetin, geraniin, corilagin, tannin, and kaempferitrin.
  • quercetin is an antioxidant. It is known.
  • Hyeoncho has been reported to have the ability to inhibit the production of intracellular oxygen radicals and to scavenge free radicals in a concentration-dependent manner, and has antioxidant and anti-inflammatory effects.
  • the herbal medicine of the present invention may be a mixture of one or more types.
  • the herbal medicine may be a mixture of two types of herbal medicine.
  • the herbal medicine may be a mixture of yam and Hyeoncho.
  • the herbal medicine may be a mixture of yam and bellflower root.
  • the herbal medicine may be a mixture of yam and Sanghwang mushroom.
  • the herbal medicine may be a mixture of yam and Cordyceps sinensis.
  • the herbal medicine may be a mixture of Hyeoncho and bellflower root.
  • the herbal medicine may be a mixture of Hyeoncho and Sanghwang mushrooms.
  • the herbal medicine may be a mixture of Hyeoncho and Cordyceps sinensis.
  • the herbal medicine may be a mixture of bellflower root and Sanghwang mushroom. In one embodiment, the herbal medicine may be a mixture of bellflower root and Cordyceps sinensis. In one specific example, the herbal medicine may be a mixture of Sanghwang mushroom and Cordyceps sinensis.
  • the herbal medicine may be a mixture of three types of herbal medicine.
  • the herbal medicine may be a mixture of yam, Hyeoncho, and bellflower root.
  • the herbal medicine may be a mixture of yam, Hyeoncho, and Sanghwang mushroom.
  • the herbal medicine may be a mixture of yam, Hyeoncho and Cordyceps sinensis.
  • the herbal medicine may be a mixture of yam, bellflower root, and sanghwang mushroom.
  • the herbal medicine may be a mixture of yam, bellflower root, and Cordyceps sinensis.
  • the herbal medicine may be a mixture of Hyeoncho, bellflower root, and Sanghwang mushroom.
  • the herbal medicine may be a mixture of Hyeoncho, bellflower root, and Cordyceps sinensis.
  • the herbal medicine may be a mixture of four types of herbal medicine.
  • the herbal medicine may be a mixture of yam, Hyeoncho, bellflower root, and Sanghwang mushroom.
  • the herbal medicine may be a mixture of yam, Hyeoncho, bellflower root, and Cordyceps sinensis.
  • the herbal medicine may be a mixture of yam, Hyeoncho, Sanghwang mushroom, and Cordyceps sinensis.
  • the herbal medicine may be a mixture of yam, bellflower root, Sanghwang mushroom, and Cordyceps sinensis.
  • the herbal medicine may be a mixture of Hyeoncho, bellflower root, Sanghwang mushroom, and Cordyceps sinensis.
  • the herbal medicine may be a mixture of five types of herbal medicine.
  • the five types of herbal medicines such as yam, Hyeoncho, bellflower root, Sanghwang mushroom, and Cordyceps sinensis can be mixed in a predetermined ratio.
  • the second active substance may include a herbal medicine alone as an active ingredient, or may include one or more pharmaceutically acceptable carriers, excipients, or diluents.
  • the term "included as an active ingredient” means that strains of the Lactobacillus genus, lysate of the strain, culture medium, or extract of the culture medium are added, and various ingredients are added as sub-ingredients for drug delivery and stabilization. It means being formulated in various forms.
  • the first active material and the second active material may be administered in combination simultaneously, sequentially, or in reverse order.
  • the term “combination therapy” or “combination administration” or “in combination” refers to any form of simultaneous or concurrent treatment using at least two separate therapeutic agents.
  • the components of the combination therapy may be administered simultaneously, sequentially, or in any order.
  • the components may be administered in any suitable manner, in different doses or at different frequencies of administration or via different routes.
  • the combined administration may be administering the Lactobacillus plantarum strain and herbal medicine simultaneously, or administering the herbal medicine after administering the Lactobacillus plantarum strain.
  • the combination therapy according to the present invention is an efficacy that can be obtained by administering one or the rest of the components of the combination therapy at a conventional dose, for example, the efficacy measured through the degree of response, response rate, time to disease progression, or survival time. More therapeutically superior can be defined as being able to provide synergistic effects. For example, if the therapeutic efficacy is superior to the efficacy obtained by using each of the above alone, the efficacy of the combination treatment is synergistic.
  • administered simultaneously is not particularly limited and means that the components of the combination therapy are administered substantially simultaneously, for example as a mixture or in an immediately following sequence.
  • the term “sequentially administered” is not particularly limited and means that the components of the combination therapy are not administered simultaneously, but are administered one by one or in batches with a specific time interval between administrations.
  • the time interval may be the same or different between the respective administrations of the components of the combination therapy and may be selected, for example, in the range of 2 minutes to 96 hours, 1 day to 7 days or 1 week, 2 weeks or 3 weeks.
  • the time interval between administrations can range from minutes to hours, for example from 2 minutes to 72 hours, 30 minutes to 24 hours, or 1 to 12 hours. Additional examples include time intervals ranging from 24 to 96 hours, 12 to 36 hours, 8 to 24 hours, and 6 to 12 hours.
  • Another aspect includes as an active ingredient a first active material comprising a Lactobacillus plantarum strain, a culture of the strain, a lysate of the strain, or a mixture thereof, and a second active material containing a herbal medicine. do or;
  • the present invention provides a pharmaceutical composition for preventing or treating cancer, which includes the first active substance as an active ingredient and the second active substance is administered in combination.
  • strain The “strain”, “first active substance”, “herbal medicine”, “second active substance”, “anticancer activity”, and “combined administration” are as described above.
  • the pharmaceutical composition can be administered to mammals, including humans, through various routes.
  • the administration method may be any commonly used method, for example, oral, dermal, intravenous, intramuscular or subcutaneous administration, and is preferably administered orally.
  • it includes a first oral preparation containing a first active substance, and a second oral preparation containing a second active substance, and the first and second oral preparations may be administered orally.
  • the oral preparation comes in the form of tablets, pills, capsules, lozenges, granules, powders, suspensions, and sachets. , or it may be in the form of syrups.
  • prevention may refer to any action that suppresses the disease state of an individual or delays the onset of the disease by administering a pharmaceutical composition according to one aspect.
  • treatment may refer to any action in which symptoms of an individual's disease state are improved or beneficially changed by administration of a pharmaceutical composition according to one aspect.
  • the composition according to one embodiment may include 0.001% by weight to 80% by weight of the Lactobacillus plantarum strain based on the total weight of the composition. Additionally, the administered dose of the Lactobacillus plantarum strain may be 0.01 mg to 10,000 mg, 0.1 mg to 1000 mg, 1 mg to 100 mg, 0.01 mg to 1000 mg, 0.01 mg to 100 mg, 0.01 mg to 10 mg, or 0.01 mg to 1 mg. .
  • the strain is included in the composition in a therapeutically effective amount or nutritionally effective concentration, for example, the strain is 10 3 to 10 16 CFU/g, 10 3 to 10 15 CFU/g, 10 3 to 10 14 CFU/g.
  • 1x10 3 to 1x10 16 CFU/g of live or dead cells may be administered once or in divided doses.
  • the dosage may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, gender, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity, and those skilled in the art will Taking these factors into consideration, the dosage can be adjusted appropriately.
  • the number of administrations can be one time or two or more times within the range of clinically acceptable side effects, and the administration site can be administered at one or two or more places.
  • the dosage per kg is the same as for humans, or, for example, the above-mentioned administration is based on the volume ratio (e.g., average value) of organs (e.g., heart, etc.) between the target animal and human.
  • the converted dose can be administered.
  • Possible routes of administration include oral, sublingual, parenteral (e.g., subcutaneous, intramuscular, intraarterial, intraperitoneal, intrathecal, or intravenous), rectal, topical (including transdermal), inhalation, and injection, or implantable device. Alternatively, it may include insertion of a substance.
  • the composition includes killed dried strains, and can be administered in an amount of 1g to 10g, 0.5g to 1.5g, 2.5g to 3.5g, or 4.5g to 5.5g, once a day to 3 times. It may be administered once.
  • the term "therapeutically effective amount” refers to an herbal medicine or method of the present invention for the method and use of the present invention that elicits a biological or medical response or desired therapeutic effect in a patient that researchers, doctors, or other clinicians wish to obtain. and the amount of a pharmaceutical composition containing herbal medicine for use.
  • the therapeutically effective amount of a herbal medicine may vary depending on factors such as the disease state, age, sex and weight of the individual, and the ability of the herbal medicine to elicit the desired response in the individual.
  • a therapeutically effective amount is also an amount in which the therapeutically beneficial effects outweigh any toxic or harmful effects.
  • the pharmaceutical composition according to one embodiment may include a pharmaceutically acceptable carrier and/or additive.
  • a pharmaceutically acceptable carrier and/or additive for example, sterilized water, physiological saline, common buffers (phosphoric acid, citric acid, other organic acids, etc.), stabilizers, salts, antioxidants (ascorbic acid, etc.), surfactants, suspending agents, isotonic agents, or preservatives.
  • it may also include combinations with organic materials such as biopolymers and inorganic materials such as hydroxyapatite, specifically collagen matrices, polylactic acid polymers or copolymers, polyethylene glycol polymers or copolymers, and chemical derivatives thereof. You can.
  • the Lactobacillus bacteria may be dissolved or dispersed in a pharmaceutically acceptable carrier, or may be frozen in a dissolved or dispersed solution state. .
  • the pharmaceutical composition may be used as a suspending agent, solubilizing agent, stabilizer, isotonic agent, preservative, anti-adsorption agent, surfactant, diluent, excipient, pH adjuster, analgesic agent, etc., if necessary depending on the administration method or formulation. Buffers, reducing agents, antioxidants, etc. may be appropriately included.
  • Pharmaceutically acceptable carriers and agents suitable for the present invention including those exemplified above, are described in detail in Remington's Pharmaceutical Sciences, 19th ed., 1995.
  • the pharmaceutical composition according to one embodiment is formulated in unit dosage form using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily performed by a person skilled in the art to which the invention pertains. It can be manufactured by or by placing it in a multi-capacity container.
  • the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or in the form of powder, granules, tablets or capsules.
  • the pharmaceutical composition is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat the disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type, severity, activity of the drug, and the type and severity of the patient's disease. It can be determined based on factors including sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, drugs used simultaneously, and other factors well known in the medical field.
  • the composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. Considering all of the above factors, it is important to administer an amount that can achieve maximum effect with the minimum amount without side effects, and this can be easily determined by a person skilled in the art.
  • the anticancer activity of the first active material may be more effective when administered in combination with the second active material.
  • Lactobacillus plantarum GB104 strain and the herbal medicines Cordyceps sinensis, yam, bellflower root, or Sanghwang mushroom are administered in combination to a tumor animal model transplanted with the mouse colon cancer cell line CT26, Lactobacillus plantarum GB104 strain It showed increased anticancer effect compared to when administered alone. Specifically, the effect of inhibiting the growth and progression of colon cancer tumors was confirmed. On average, compared to the control group, the experimental group administered GB104 and herbal medicine in combination showed a reduction in tumor volume by 10% to 90% or tumor weight by 10% to 50%.
  • the colon cancer tumor volume is 90% based on 100% of the colon cancer tumor volume of the negative control group that did not administer the strain or herbal medicine.
  • the colon cancer tumor weight is reduced by 50% based on 100% of the colon cancer tumor weight of the negative control group that did not administer the strain or herbal medicine. or less, 45% or less, 40% or less, 35% or less, 10 to 50%, 10 to 45%, 10 to 40%, 10 to 35%, 10 to 30%, 15 to 50%, 15 to 45%, 15 It may have activity that decreases to 40%, 15 to 35%, 15 to 30%, 20 to 50%, 20 to 45%, 20 to 40%, 20 to 35%, or 20 to 30%. .
  • Lactobacillus Plantarum GB104 strain and herbal medicine specifically, Herbal Root
  • a tumor animal model transplanted with the mouse colon cancer cell line MC-38 when the Lactobacillus Plantarum GB104 strain is administered alone. It showed increased anti-cancer effect. Specifically, the effect of inhibiting the growth and progression of colon cancer tumors was confirmed. On average, compared to the control group, in the experimental group administered GB104 and herbal medicine together, the tumor volume was reduced by 10% to 90% and the tumor weight was reduced by 10% to 50%.
  • the colon cancer tumor volume is 90% based on 100% of the colon cancer tumor volume of the negative control group that did not administer the strain or herbal medicine.
  • the colon cancer tumor weight is reduced by 50% based on 100% of the colon cancer tumor weight of the negative control group that did not administer the strain or herbal medicine. or less, 45% or less, 40% or less, 35% or less, 10 to 50%, 10 to 45%, 10 to 40%, 10 to 35%, 10 to 30%, 15 to 50%, 15 to 45%, 15 It may have activity that decreases to 40%, 15 to 35%, 15 to 30%, 20 to 50%, 20 to 45%, 20 to 40%, 20 to 35%, or 20 to 30%. .
  • Another aspect is a first activity comprising at least one member selected from the group consisting of Lactobacillus plantarum strains, cultures of the strains, lysates of the strains, or extracts of the cells, cultures, and lysates. or containing a second active substance including a substance and herbal medicine as an active ingredient;
  • the present invention provides a health functional food for preventing or improving cancer, which includes the first active substance as an active ingredient and the second active substance is administered in combination.
  • Another aspect is a first activity comprising at least one member selected from the group consisting of Lactobacillus plantarum strains, cultures of the strains, lysates of the strains, or extracts of the cells, cultures, and lysates. or containing a second active substance including a substance and herbal medicine as an active ingredient;
  • the present invention provides a food composition for preventing or improving cancer, which includes the first active substance as an active ingredient and the second active substance is administered in combination.
  • strain The “strain”, “first active substance”, “herbal medicine”, “second active substance”, “anticancer activity”, and “combined administration” are as described above.
  • the food composition can be administered to mammals, including humans, through various routes.
  • the administration method may be any commonly used method, for example, oral, dermal, intravenous, intramuscular or subcutaneous administration, and is preferably administered orally.
  • it includes a first oral preparation containing a first active substance, and a second oral preparation containing a second active substance, and the first and second oral preparations may be administered orally.
  • the oral preparation comes in the form of tablets, pills, capsules, lozenges, granules, powders, suspensions, and sachets. , or it may be in the form of syrups.
  • the health functional food may further include a foodologically acceptable carrier.
  • the term “foodologically acceptable” means that the compound exhibits non-toxic properties to cells or humans exposed to the compound.
  • the term “improvement” may refer to any action that at least reduces the severity of a parameter related to the condition being treated, for example, a symptom.
  • the health functional food can be used simultaneously or separately with a drug for treatment before or after the onset of the disease in order to prevent or improve cancer.
  • the active ingredient can be added directly to the food or used together with other foods or food ingredients, and can be used appropriately according to conventional methods.
  • the mixing amount of the active ingredient can be appropriately determined depending on the purpose of use (prevention or improvement).
  • the health functional food may be added in an amount of about 15% by weight or less, more specifically about 10% by weight or less, based on the raw materials.
  • the amount may be below the above range.
  • the health functional food may be formulated with one selected from the group consisting of tablets, pills, powders, granules, powders, capsules, and liquid formulations, further including one or more of carriers, diluents, excipients, and additives.
  • Foods to which compounds according to one aspect can be added include various foods, powders, granules, tablets, capsules, syrups, beverages, gum, tea, vitamin complexes, health functional foods, etc.
  • the carriers, excipients, diluents and additives include lactose, dextrose, sucrose, sorbitol, mannitol, erythritol, starch, gum acacia, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate, microcrystalline cellulose. , polyvinylpyrrolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water, sugar syrup, methylcellulose, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil. It may be at least one selected from.
  • the health functional food may contain other ingredients as essential ingredients without any particular restrictions.
  • the health functional food may contain various flavoring agents or natural carbohydrates as additional ingredients.
  • natural carbohydrates include monosaccharides such as glucose, fructose, etc.; disaccharides such as maltose, sucrose, etc.; and polysaccharides, such as common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavoring agents thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)
  • synthetic flavoring agents sacharin, aspartame, etc.
  • the ratio of the natural carbohydrates can be appropriately determined by the selection of a person skilled in the art.
  • health functional foods include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavors, colorants and thickening agents (cheese, chocolate, etc.), pectic acid and salts thereof. , alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. These components can be used independently or in combination, and the proportions of these additives can also be appropriately selected by those skilled in the art.
  • the health functional food may be provided by mixing with conventionally known health functional food for preventing or improving cancer or other existing health functional food, and the health functional food for preventing or improving cancer is known to be a metabolic disease. It may be a health functional food for the prevention or improvement of, an existing health functional food, or a newly developed health functional food.
  • the health functional food contains other health functional foods that have the effect of preventing or improving cancer, it is important to mix the amount to obtain the maximum effect with the minimum amount without side effects, and this can be easily determined by a person skilled in the art. there is.
  • the food composition for preventing or improving cancer includes all forms such as functional food, nutritional supplement, health food, and food additives, and the above type of food composition It can be manufactured in various forms according to conventional methods known in the art.
  • compositions herein may be considered food supplements.
  • Food supplements also known as dietary supplements or nutritional supplements, can be considered another pharmaceutical product. It is intended to supplement the diet and provide nutrients or beneficial ingredients that may not be available or consumed in sufficient amounts in the normal diet.
  • Most food supplements are considered foods, but sometimes they are considered drugs, natural health products, or nutraceutical products.
  • food supplements include health functional foods. Food supplements are usually sold over the counter without a prescription. When food supplements take the form of pills or capsules, they contain the same excipients used in pharmaceuticals. However, food supplements may take the form of food fortified with some nutrients (e.g. infant formula). Accordingly, in certain embodiments, the compositions of the present invention are food supplements.
  • composition according to the present invention can be administered as is or mixed with a suitable edible liquid or solid or in the form of tablets, pills, capsules, lozenges, granules, powders. ), suspensions, sachets, syrups, or may be freeze-dried in the form of unit doses. It may also be in the form of monodoses of a lyophilized composition that are mixed in a separate liquid container provided prior to administration.
  • composition of the present invention may be included in various edible foods and foods such as milk products for infants.
  • the term "edible product” has a broad sense and includes any product that can be ingested by an animal, in any form (e.g., a product that can be consumed by the sense organs). products that can be imported).
  • the term "food product” is understood as an edible product that provides nutritional support to the body.
  • Foods of particular interest are food supplements and infant formulas.
  • Foods preferably include oatmeal porridge, lactic acid fermented foods, resistant starch, dietary fibers, carbohydrates, proteins and glycated proteins. Includes carrier materials such as glycosylated proteins.
  • bacterial cells of the invention are homogenized with other ingredients, such as cereals or powdered milk, to form infant formula.
  • Another aspect is a first activity comprising at least one member selected from the group consisting of Lactobacillus plantarum strains, cultures of the strains, lysates of the strains, or extracts of the cells, cultures, and lysates. or containing a second active substance including a substance and herbal medicine as an active ingredient;
  • the present invention provides a kit for preventing or treating cancer, which includes the first active substance as an active ingredient and the second active substance is administered in combination.
  • Another aspect is a first activity comprising at least one member selected from the group consisting of Lactobacillus plantarum strains, cultures of the strains, lysates of the strains, or extracts of the cells, cultures, and lysates. or containing a second active substance including a substance and herbal medicine as an active ingredient;
  • a first activity comprising at least one member selected from the group consisting of Lactobacillus plantarum strains, cultures of the strains, lysates of the strains, or extracts of the cells, cultures, and lysates. or containing a second active substance including a substance and herbal medicine as an active ingredient;
  • it provides a method of delivering a drug into a subject comprising administering to an subject in need a composition containing the first active substance as an active ingredient and co-administering the second active substance.
  • Another aspect is a first activity comprising at least one member selected from the group consisting of Lactobacillus plantarum strains, cultures of the strains, lysates of the strains, or extracts of the cells, cultures, and lysates. or containing a second active substance including a substance and herbal medicine as an active ingredient; Alternatively, it provides a method for preventing or treating cancer, comprising administering to an individual in need a composition containing the first active ingredient as an active ingredient and administering the second active ingredient in combination.
  • strain The “strain”, “first active substance”, “herbal medicine”, “second active substance”, “anticancer activity”, and “combined administration” are as described above.
  • the individual may be an individual suffering from cancer. Additionally, the subject may be a mammal, and preferably may be a human.
  • the administration route, dosage, and frequency of administration of the Lactobacillus Plantarum GB104 strain and herbal medicine can be administered to the subject in various methods and amounts depending on the patient's condition and the presence or absence of side effects, and the optimal administration method, dosage, and administration The number of times can be selected within an appropriate range by a person skilled in the art.
  • it may be administered in combination with other drugs known to have therapeutic effects on cancer diseases (e.g., the herbal medicine described above) or physiologically active substances, or may be formulated in the form of a combination preparation with other drugs. .
  • Lactobacillus plantarum strain or the culture medium of the strain, can not only inhibit the proliferation of cancer cells or induce the death of cancer cells, but when administered in combination with herbal medicine, it has a synergistic effect on inhibiting the proliferation of cancer cells and tumors. It can be usefully used to prevent, treat or improve cancer in the form of a composition or health functional food.
  • Figure 1 is a graph showing the results of analyzing the cell survival rate after treating the human colon cancer cell line HCT116 with culture supernatants of GB104 and other strains, respectively.
  • Figure 2 is a graph showing the results of confirming the cell cycle after treating the human colon cancer cell line HCT116 with culture supernatants of GB104 and the comparison strain (GBCC_F0077), respectively.
  • Figure 3 is a graph showing the results of confirming cell death after treating the human colon cancer cell line HCT116 with culture supernatants of GB104 and the comparison strain (GBCC_F0077), respectively.
  • Figure 4 is a graph showing the results of analyzing the synergistic effect by measuring tumor volume after co-administration of GB104 and herbal medicine (Cordyceps sinensis, yam, bellflower root, and Sanghwang mushroom) in an allograft CT26 mouse colon carcinoma model.
  • Figure 5 is a graph showing the results of analyzing the synergy effect by measuring tumor weight after co-administration of GB104 and herbal medicine (Cordyceps sinensis, yam, bellflower root, and Sanghwang mushroom) in an allograft CT26 mouse colon carcinoma model.
  • Figure 6 is a graph showing the results of comparative analysis by measuring tumor volume after single and combined administration of GB104 and herbal medicine (yam, bellflower root) in an allograft CT26 mouse colon carcinoma model.
  • Figure 7 is a graph showing the results of analyzing the synergy effect by measuring the tumor volume after co-administration of GB104 and herbal medicine (Hyeoncho) in the allograft MC-38 mouse colon carcinoma model.
  • Figure 8 is a graph showing the results of analyzing the synergy effect by measuring tumor weight after co-administration of GB104 and herbal medicine (Hyeoncho) in the allograft MC-38 mouse colon carcinoma model.
  • Figure 9 is a graph showing the results of comparative analysis by measuring tumor volume after single and combined administration of GB104 and herbal medicine (Hyeoncho) in the allograft MC-38 mouse colon carcinoma model.
  • Lactobacillus Plantarum GB104 was isolated from a vaginal sample of a healthy woman who visited the hospital for health checkup. First, vaginal samples were collected with a swab, inoculated into Rogosa SL (MRS) plate medium, and cultured in an anaerobic chamber at 37°C for 48 hours. When bacterial colonies grew, single colonies were subcultured onto new MRS plate medium for pure isolation. After pure isolation, the strain was cultured using MRS medium. Next, among the cultured strains, Lactobacillus plantarum has an inhibitory effect on fat cell accumulation and has low cytotoxicity. Strain GB104 was finally selected.
  • MRS Rogosa SL
  • the 16S rRNA gene sequence obtained through PCR using primers targeting the 16S rRNA gene was analyzed by Sanger sequencing method, and Lactobacillus Plantarum
  • the 16S rRNA sequence of GB104 is shown as SEQ ID NO: 1.
  • the present inventors named the GB104 strain as " Lactobacillus plantarum GB104" (Accession number: KCTC 14107BP) and transferred it to the Korean collection for type cultures (KCTC) at the Korea Research Institute of Bioscience and Biotechnology in 2020. It was deposited on the 14th of February.
  • Lactobacillus plantarum was changed to Lactiplantibacillus plantarum .
  • the changed strain names of existing strains are described interchangeably.
  • L. Plantarum culture supernatants including L. Plantarum GB104 strain
  • L. Plantarum GB104 strain were treated using human colon cancer cell lines, and cell viability was screened through MTT analysis.
  • Human colon cancer cell line HCT116 cells were dispensed into each well of a 96-well plate at 2 ⁇ 10 3 cells and cultured for 24 hours. Then, 10% culture supernatant of various L. Plantarum strains was added in a culture medium supplemented with DFMO and aminoguanidine. concentration and cultured for 72 hours under conditions of 37°C and 5% CO 2 . The culture supernatant was obtained by culturing the L. Plantarum strain in MRS medium, precipitating the strain by centrifugation, collecting only the supernatant, and filtering it through a 0.22 ⁇ m filter.
  • MTT Cell Proliferation Kit I
  • Figure 1 is a graph showing the results of analyzing the cell survival rate after treating the human colon cancer cell line HCT116 with culture supernatants of GB104 and other strains, respectively.
  • L. Plantarum GB104 culture supernatant was treated using the human colon cancer cell line, and changes in the cancer cell cycle were confirmed through flow cytometry.
  • Human colon cancer cell line HCT116 cells were dispensed into each well of a 6-well plate at 5 ⁇ 10 4 cells and cultured for 24 hours. Then, 10% of the culture supernatant of the L. Plantarum GB104 strain was added in a culture medium supplemented with DFMO and aminoguanidine. concentration and cultured for 48 hours under conditions of 37°C and 5% CO 2 . The culture supernatant was obtained by culturing the L. Plantarum strain in MRS medium, precipitating the strain by centrifugation, collecting only the supernatant, and filtering it through a 0.22 ⁇ m filter.
  • Figure 2 is a graph showing the results of confirming the cell cycle after treating the human colon cancer cell line HCT116 with culture supernatants of GB104 and the comparison strain (GBCC_F0077), respectively.
  • L. Plantarum GB104 culture supernatant was treated using human colon cancer cell line, and the cancer cell killing effect was confirmed through flow cytometry.
  • Human colon cancer cell line HCT116 cells were dispensed into each well of a 6-well plate at 5 ⁇ 10 4 cells and cultured for 24 hours. Then, 10% of the culture supernatant of the L. Plantarum GB104 strain was added in a culture medium supplemented with DFMO and aminoguanidine. concentration and cultured for 48 hours under conditions of 37°C and 5% CO 2 . The culture supernatant was obtained by culturing the L. Plantarum strain in MRS medium, precipitating the strain by centrifugation, collecting only the supernatant, and filtering it through a 0.22 ⁇ m filter. After 48 hours, the cells were removed by treatment with trypsin-EDTA and then harvested by centrifugation.
  • Figure 3 is a graph showing the results of confirming cell death after treating the human colon cancer cell line HCT116 with culture supernatants of GB104 and the comparison strain (GBCC_F0077), respectively.
  • mice with tumor sizes within a certain range were selected and classified so that the average tumor size of each group was the same.
  • L. Plantarum GB104 strain alone, L. Plantarum GB104 strain and Cordyceps sinensis, yam, and bellflower root were treated.
  • each of the Sanghwang mushrooms was orally administered to the animal model every day until just before the end of the test.
  • the concentration of the administered strain was 1x109 CFU per mouse, and all herbal medicines were administered at 1mg per mouse.
  • Table 1 shows the mean and standard deviation of the tumor size of mice in each group at 5, 7, 9, 11, 13, 15, and 17 days after injection of the colon cancer cell line CT26.
  • Figure 4 is a graph showing the results of analyzing the synergistic effect by measuring tumor volume after co-administration of GB104 and herbal medicine (Cordyceps sinensis, yam, bellflower root, and Sanghwang mushroom) in an allograft CT26 mouse colon carcinoma model.
  • Figure 5 is a graph showing the results of analyzing the synergy effect by measuring tumor weight after co-administration of GB104 and herbal medicine (Cordyceps sinensis, yam, bellflower root, and Sanghwang mushroom) in an allograft CT26 mouse colon carcinoma model.
  • Figure 6 is a graph showing the results of comparative analysis by measuring tumor volume after single and combined administration of GB104 and herbal medicine (yam, bellflower root) in an allograft CT26 mouse colon carcinoma model.
  • mice with tumor sizes within a certain range were selected and classified so that the average tumor size of each group was the same.
  • L. Plantarum GB104 strain alone, L. Plantarum GB104 strain and sage root combination were treated as described above. It was orally administered to the animal model every day until just before the end of the test. The concentration of the administered strain was 1x109 CFU per mouse, and Hyeoncho was administered at 1 mg per mouse.
  • Table 2 shows the mean and standard deviation of the tumor size of mice in each group at 6, 9, 12, 14, 16, 19, and 21 days after injection of the colon cancer cell line MC-38.
  • Figure 7 is a graph showing the results of analyzing the synergy effect by measuring the tumor volume after co-administration of GB104 and herbal medicine (Hyeoncho) in the allograft MC-38 mouse colon carcinoma model.
  • Figure 8 is a graph showing the results of analyzing the synergy effect by measuring tumor weight after co-administration of GB104 and herbal medicine (Hyeoncho) in the allograft MC-38 mouse colon carcinoma model.
  • Figure 9 is a graph showing the results of comparative analysis by measuring tumor volume after single and combined administration of GB104 and herbal medicine (Hyeoncho) in the allograft MC-38 mouse colon carcinoma model.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition pour le traitement du cancer à l'aide d'une polythérapie, comprenant une souche de Lactobacillus plantarum et un médicament à base de plantes. La souche de Lactobacillus plantarum ou un milieu de culture de la souche peut non seulement inhiber la prolifération des cellules cancéreuses ou induire la mort des cellules cancéreuses, mais présente également, lorsqu'elle est administrée en combinaison avec un médicament à base de plantes, un effet synergique sur l'inhibition de la prolifération des cellules cancéreuses et des tumeurs, et peut ainsi être utilement utilisée pour prévenir, traiter ou soulager le cancer sous la forme d'une composition pharmaceutique ou d'un aliment fonctionnel de santé.
PCT/KR2023/014310 2022-09-20 2023-09-20 Composition pour la prévention ou le traitement du cancer à l'aide d'une polythérapie, comprenant une souche de lactobacillus plantarum et un médicament à base de plantes WO2024063543A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2022-0118923 2022-09-20
KR20220118923 2022-09-20
KR1020230125600A KR20240040655A (ko) 2022-09-20 2023-09-20 락토바실러스 플란타룸 균주 및 한약재를 포함하는 병용 요법을 이용한 암 예방 또는 치료용 조성물
KR10-2023-0125600 2023-09-20

Publications (1)

Publication Number Publication Date
WO2024063543A1 true WO2024063543A1 (fr) 2024-03-28

Family

ID=90454984

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/014310 WO2024063543A1 (fr) 2022-09-20 2023-09-20 Composition pour la prévention ou le traitement du cancer à l'aide d'une polythérapie, comprenant une souche de lactobacillus plantarum et un médicament à base de plantes

Country Status (1)

Country Link
WO (1) WO2024063543A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100911115B1 (ko) * 2007-06-15 2009-08-11 주식회사 씨티씨바이오 내산성, 내담즙산성 및 항균 효과를 가진 신규한 유산균 및 이를 포함하는 조성물
KR20100079303A (ko) * 2008-12-31 2010-07-08 주식회사한국신약 상황버섯과 동충하초를 포함하는 항암용 건강식품
CN104127443A (zh) * 2014-07-25 2014-11-05 吉林省农业科学院 一种乳酸菌与人参多糖组合物及其制备方法与应用
KR20180105842A (ko) * 2017-03-16 2018-10-01 주식회사 알엔에이 약리학적 활성성분이 축적된 미생물 제제
KR20210086540A (ko) * 2019-12-31 2021-07-08 주식회사 지아이바이옴 락토바실러스 플란타럼 균주 및 이를 포함하는 대사질환의 예방 또는 치료용 조성물
KR20210090570A (ko) * 2020-01-10 2021-07-20 이뮤노바이옴 주식회사 신규한 락토바실러스 플란타룸(Lactobacillus plantarum) 균주, 균주 유래 다당체 및 이의 용도
KR20220028943A (ko) * 2020-08-31 2022-03-08 주식회사 리비옴 항암 활성을 갖는 락토바실러스 플란타룸 미생물, 그를 포함하는 조성물 및 그를 이용한 암 예방 또는 치료 방법
KR20220131844A (ko) * 2021-03-22 2022-09-29 주식회사 지아이바이옴 락토바실러스 플란타럼 gb104 균주 및 이를 포함하는 암 예방 또는 치료용 조성물

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100911115B1 (ko) * 2007-06-15 2009-08-11 주식회사 씨티씨바이오 내산성, 내담즙산성 및 항균 효과를 가진 신규한 유산균 및 이를 포함하는 조성물
KR20100079303A (ko) * 2008-12-31 2010-07-08 주식회사한국신약 상황버섯과 동충하초를 포함하는 항암용 건강식품
CN104127443A (zh) * 2014-07-25 2014-11-05 吉林省农业科学院 一种乳酸菌与人参多糖组合物及其制备方法与应用
KR20180105842A (ko) * 2017-03-16 2018-10-01 주식회사 알엔에이 약리학적 활성성분이 축적된 미생물 제제
KR20210086540A (ko) * 2019-12-31 2021-07-08 주식회사 지아이바이옴 락토바실러스 플란타럼 균주 및 이를 포함하는 대사질환의 예방 또는 치료용 조성물
KR20210090570A (ko) * 2020-01-10 2021-07-20 이뮤노바이옴 주식회사 신규한 락토바실러스 플란타룸(Lactobacillus plantarum) 균주, 균주 유래 다당체 및 이의 용도
KR20220028943A (ko) * 2020-08-31 2022-03-08 주식회사 리비옴 항암 활성을 갖는 락토바실러스 플란타룸 미생물, 그를 포함하는 조성물 및 그를 이용한 암 예방 또는 치료 방법
KR20220131844A (ko) * 2021-03-22 2022-09-29 주식회사 지아이바이옴 락토바실러스 플란타럼 gb104 균주 및 이를 포함하는 암 예방 또는 치료용 조성물

Similar Documents

Publication Publication Date Title
US7785581B2 (en) Composition and method for reducing feces toxins and treating digestive disorders
WO2019199094A1 (fr) Nouvelle souche de bifidobacterium longum ou de lactobacillus rhamnosus ayant pour effet de prévenir ou de traiter l'obésité, et utilisation correspondante
WO2022203303A1 (fr) Souche de lactobacillus plantarum gb104 et composition la comprenant destinée à la prévention ou au traitement du cancer
KR102173168B1 (ko) 류코노스톡속 균주를 포함하는 장 기능 개선용 조성물
WO2015030283A1 (fr) Composition destinée à prévenir et traiter la fatigue liée au cancer contenant de la poudre de ginseng traitée ou de l'extrait de ginseng traité comprenant un constituant de ginsénoside amélioré
WO2018090983A9 (fr) Composé de saponine pour améliorer la microflore intestinale, son procédé de préparation et son utilisation
KR102041916B1 (ko) 신장질환 진행 억제 및 예방용 프로바이오틱스 및 이를 포함하는 신장질환 진행 억제 및 예방용 조성물
WO2017183902A1 (fr) Composition contenant des extraits de artemisia capillaris, sanguisorba officinalis et curcuma longa et un agent antiviral, en tant que principes actifs, destinée à prévenir ou traiter une maladie du foie
WO2016190566A9 (fr) Composition pharmaceutique ou aliment naturel fonctionnel pour la prévention et le traitement de maladies métaboliques, contenant un extrait aqueux de pleurotus eryngii var. ferulae (pf.) en tant que principe actif
WO2016072655A1 (fr) Composition pour améliorer, traiter ou prévenir la constipation comprenant un produit fermenté renfermant des bactéries lactiques de graines de cassia comme ingrédient efficace, et son procédé de préparation
WO2020226467A1 (fr) Souche d'enterococcus lactis wik0107 ayant des effets de régulation des fonctions immunitaires et d'atténuation des maladies inflammatoires chroniques intestinales et son utilisation
WO2020226468A1 (fr) Souche de pediococcus inopinatus ｗikim0108 ayant un effet de régulation de la fonction immunitaire et de soulagement d'une maladie intestinale inflammatoire et son utilisation
WO2020139020A2 (fr) Kimchi pour la prévention ou le traitement de maladies associées à helicobacter pylori
WO2024063543A1 (fr) Composition pour la prévention ou le traitement du cancer à l'aide d'une polythérapie, comprenant une souche de lactobacillus plantarum et un médicament à base de plantes
WO2023068855A1 (fr) Composition pour le soulagement, la prévention ou le traitement du cancer à l'aide d'une souche de veillonella parvula ayant une activité anticancéreuse
WO2016093613A2 (fr) Composition pour la prévention ou le traitement d'une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma
WO2023058801A1 (fr) Composition pour soulager, prévenir ou traiter un trouble intestinal, comprenant une souche de lactobacillus acidophilus kbl402 ou kbl409
WO2022039514A1 (fr) Composition pour le traitement de maladies cérébrales comprenant lactobacillus sakei ou des vésicules extracellulaires dérivées de celui-ci en tant que principe actif
WO2021261929A1 (fr) Nouvelle souche de lactobacillus reuteri et utilisation associée
KR20240040655A (ko) 락토바실러스 플란타룸 균주 및 한약재를 포함하는 병용 요법을 이용한 암 예방 또는 치료용 조성물
KR20130131973A (ko) 오리나무 수피 추출물 및 유산균을 포함하는 항우식성 조성물
WO2024063545A1 (fr) Composition comprenant une souche de lactobacillus plantarum pour améliorer la composition de métabolite intestinal
WO2024058320A1 (fr) Composition pour prévenir, soulager ou traiter une maladie intestinale
WO2023229263A1 (fr) Composition pour prévenir, traiter ou atténuer des maladies métaboliques comprenant une souche de lactobacillus plantarum nchbl-004 ou un milieu de culture de celle-ci
WO2022158922A2 (fr) Composition comprenant une souche de propionibacterium freudenreichii mj2 utilisée en tant que principe actif pour la prévention, le traitement ou l'atténuation de la polyarthrite rhumatoïde

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23868595

Country of ref document: EP

Kind code of ref document: A1